HB1109 creates the “Medetomidine and Xylazine Consumer Protection Act” within the Health-General Article. The bill restricts retail sales of medetomidine and xylazine products by requiring purchasers to provide proof that the products will be used for an institutional, veterinary, or scientific purpose, and it bars sales or exposure for sale to anyone under 21. It also defines “retailer” broadly to include manufacturers, wholesalers, corporations, partnerships, LLCs, firms, online platforms, and other businesses operating in Maryland.
The bill requires retailers that prepare, distribute, sell, or offer these products to keep sales records, including copies of identification used to verify age and documents showing the purchaser’s intended use. Violations are subject to civil penalties of up to $3,000 for a first violation and $6,500 for each subsequent violation. The Maryland Department of Health must adopt regulations to implement the subtitle, and all civil penalties collected are directed to the Maryland Substance Abuse Fund.
Impact
HB1109 would add a new subtitle to the Health-General Article and amend the Maryland Substance Abuse Fund provisions to include civil penalties collected under the new law. It would impose new compliance, documentation, and age-verification obligations on retailers of medetomidine and xylazine products, while creating a state enforcement mechanism through civil penalties and regulatory authority for the Department of Health. The bill would primarily affect businesses that handle these substances, including online sellers and other entities doing business in the state, and would channel penalty revenue into substance abuse-related funding.
Sentiment
Based on the bill text and available context, the measure appears to be framed as a public health and consumer protection initiative rather than a controversial criminal penalty expansion. No committee transcript or vote record is provided, so there is no documented floor or committee sentiment to assess. The bill’s structure suggests support for tighter controls on substances associated with misuse, with an emphasis on limiting access and directing penalty revenue to substance abuse treatment or prevention funding.
Contention
The main points of potential contention are the breadth of the sales restrictions and the compliance burden placed on retailers. Requiring proof of institutional, veterinary, or scientific intent may be difficult to administer in practice, especially for online platforms and businesses that do not routinely sell controlled or restricted substances. Another possible issue is the age threshold of 21 and the broad definition of retailer, which could capture a wide range of business models. Supporters would likely emphasize public health and misuse prevention, while opponents may focus on regulatory burden, ambiguity in proof-of-intent standards, and enforcement challenges.